Related Experiment Video
Updated: Oct 5, 2025

Modeling an Enzyme Active Site using Molecular Visualization Freeware
Published on: December 25, 2021
Molecular simulations of zwitterlation-induced conformation and dynamics variation of glucagon-like peptide-1 and
Qi Qiao1, Lirong Cai1, Qing Shao1
1Chemical and Materials Engineering Department, University of Kentucky, Lexington, Kentucky 40506, USA. qshao@uky.edu.
Abstract:
Zwitterionic materials have shown their ability to improve the circulation time and stability of proteins. Zwitterionic peptides present unique potential because genetic technology can fuse them to any wild-type protein. One critical question is the effect of the fusing zwitterionic peptides on the conformation and dynamics of the original protein domain. To shed light on this question, we investigate the conformation and dynamics of six artificial proteins composed of two small therapeutic polypeptide and protein (glucan-like peptide-1 and insulin) and a zwitterionic (glutamic acid-lysine)10 peptide in an explicit solvent using molecular dynamics simulations. The zwitterionic peptide is fused to the N- and C-terminal of the glucan-like peptide-1 and the chain A and B of the insulin. We analyze the conformation and dynamics variation of the polypeptide and protein domain using root mean square deviation, root mean square fluctuation, solvent accessible surface area, and secondary structure distributions. The simulation results show that the zwitterlation induces substantial changes in the conformation of the glucan-like peptide-1 and a moderate change in the conformation of the insulin, while the two polypeptide and protein remain folded. The glucan-like peptide-1 presents a full α-helix conformation when zwitterlated at the C-terminal. The zwitterionic location also plays a role in the conformational change. These zwitterlation-induced conformation variations indicate a comprehensive relationship between zwitterlation and protein stability and activity.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Protein and Protein Structure
A protein's shape is critical to its function. For example, an enzyme...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Fischer Projections
Insulin Secretory Vesicles

